PUMA BIOTECHNOLOGY INC

PBYINASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
7.51 USD
↘ 0.03 (0.40%)AT CLOSE (11:59 AM EDT)
7.50
↘ 0.01 (0.13%)
POST MARKET (AS OF 05:05 PM EDT)
Post Market
AS OF 05:05 PM EDT
7.50
↘ 0.01 (0.13%)
🔴Market: CLOSED
Open?$7.50
High?$7.70
Low?$7.44
Prev. Close?$7.54
Volume?193.1K
Avg. Volume?266.6K
VWAP?$7.53
Rel. Volume?0.72x
Bid / Ask
Bid?$6.90 × 9.0K
Ask?$7.75 × 100
Spread?$0.85
Midpoint?$7.33
Valuation & Ratios
Market Cap?382.1M
Shares Out?50.9M
Float?38.1M
Float %?75.5%
P/E Ratio?12.28
P/B Ratio?2.93
EPS?$0.61
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.98Adequate
Quick Ratio?1.91Adequate
Cash Ratio?0.36Low
Debt/Equity?0.17Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
12.3CHEAP▾
P/B?
2.93CHEAP▾
P/S?
1.67CHEAP▾
P/FCF?
9.2CHEAP▾
EV/EBITDA?
7.8CHEAP▾
EV/Sales?
1.64CHEAP▾
Returns & Efficiency
ROE?
23.9%STRONG▾
ROA?
14.4%STRONG▾
Cash Flow & Enterprise
FCF?$41.7M
Enterprise Value?$375.0M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Employees
179
Market Cap
383.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.pumabiotechnology.com
Listed
2012-03-21
Address
10880 WILSHIRE BLVD.
LOS ANGELES, CA 90024
Phone: (424) 248-6500
MarketsMoversWatchlist